DrugPatentWatch – Pharmaceutical and Biotechnology Business Intelligence

100 Folgen

1. Key Factors for Choosing the Right CDMO

   Vom: 28.8.2023
2. Strategies to Maximize Product Value Amid Loss of Exclusivity in the Pharmaceutical Industry

   Vom: 21.8.2023
3. Unsuccessful Regulatory Filings for Biosimilar Approval: A Comprehensive Review

   Vom: 15.8.2023
4. Drug Patent Reports now available on Amazon

   Vom: 14.8.2023
5. Artificial Intelligence and Machine Learning in Drug Discovery and Development

   Vom: 10.8.2023
6. Prevalence and timing of authorized generics in the US market

   Vom: 8.8.2023
7. Insights into Shifting Dynamics: Orange Book and Biologic PTAB Trends

   Vom: 7.8.2023
8. The Evolution of Reverse Payment Cases: Courts and Agencies’ Approaches in Pharma Litigation

   Vom: 5.8.2023
9. Understanding the Impact of Authorized Generics on Drug Pricing: The Entacapone Case Study

   Vom: 2.8.2023
10. Review of 505(b)(2) Drug Products Approved by USFDA from 2010 to 2020: A Focus on Intellectual Property and Regulatory Considerations

    Vom: 28.7.2023
11. DrugPatentWatch reveals NIH funding for patents

    Vom: 27.7.2023
12. Filing Strategies for Maximizing Pharma Patents

    Vom: 25.7.2023
13. DrugChatter Featured Questions

    Vom: 8.6.2023
14. DrugChatter.com: AI Chat for Biopharmaceutical Drug Insights

    Vom: 22.5.2023
15. NPR and DrugPatentWatch – Can drug injector pens be swapped?

    Vom: 16.5.2023
16. Utilizing 505(b)(2) Regulatory Pathway for New Drug Applications: An Overview on the Advanced Formulation Approach and Challenges

    Vom: 19.4.2023
17. Social Return on Investment

    Vom: 6.9.2022
18. CDCDB: A large and continuously updated drug combination database

    Vom: 7.6.2022
19. DrugPatentWatch named “Best of the Web” by Genetic Engineering News

    Vom: 2.5.2022
20. The value of method of use patent claims in protecting your therapeutic assets

    Vom: 5.4.2022